Ludwig opens new Branch in Switzerland to focus on basic and applied immunotherapy research.
Phase 3 trial confirms power of combination immunotherapy for advanced melanoma.
Phase 2 trial identifies genetic malfunction that makes many cancers vulnerable to PD-1 blockade.
Proof of principle study could lead to more reliable screening tests.
Meet our scientists